2,043,823 Shares in West Pharmaceutical Services, Inc. $WST Bought by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon bought 2.04 million shares of West Pharmaceutical Services worth approximately $733.7 million, acquiring a 2.9% stake. Institutional investors collectively own 93.9% of the company.
• West Pharmaceutical Services exceeded quarterly expectations, reporting $2.37 in EPS versus the $2.08 consensus and revenue of $872.3 million, up 13.8% year over year.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $368.08, compared with its reported price of $354.53.

Bank of New York Mellon Corp purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,043,823 shares of the medical instruments supplier's stock, valued at approximately $733,733,000. Bank of New York Mellon Corp owned about 2.90% of West Pharmaceutical Services as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Avalon Trust Co acquired a new stake in West Pharmaceutical Services during the second quarter worth about $28,000. Elyxium Wealth LLC bought a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $25,000. Bayban acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter worth approximately $27,000. Private Trust Co. NA raised its position in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 61 shares during the period. Finally, DV Equities LLC bought a new stake in shares of West Pharmaceutical Services in the 4th quarter worth approximately $28,000. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Up 0.5%

WST stock opened at $354.53 on Friday. The firm has a market cap of $24.95 billion, a PE ratio of 45.39, a P/E/G ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a 50 day simple moving average of $348.11 and a 200 day simple moving average of $299.38.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company's quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services's dividend payout ratio is 11.27%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on WST shares. Weiss Ratings raised West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 7th. Barclays upgraded West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. TD Cowen reissued a "buy" rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They set an "outperform" rating and a $447.00 price target on the stock. Finally, Morgan Stanley upped their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source